Novartis AG v. Union of India

Novartis AG v. Union of India was a landmark 2013 decision of the Supreme Court of India concerning patentability standards for pharmaceuticals, specifically a patent application by Novartis for the cancer drug Glivec (imatinib mesylate). The judgment interpreted Section 3(d) of the Patents Act, 1970 (India) and shaped Indian intellectual property policy, with wide implications for multinational corporations, generic drug manufacturers, public health advocates, and international trade negotiations.

Background

The dispute arose after Novartis filed a patent application for the beta crystalline form of imatinib mesylate, seeking protection beyond the original imatinib base first patented elsewhere by Ciba-Geigy and later by Novartis International AG. The application was opposed by Indian generic firms including Cipla, Natco Pharma, and Lee Pharma, invoking provisions of the Patents Act, 1970 (India) and citing prior art such as earlier imatinib salts and polymorphs disclosed in patent families filed in jurisdictions like the European Patent Office and the United States Patent and Trademark Office. The case moved from the Controller General of Patents, Designs and Trade Marks to the Intellectual Property Appellate Board (India), then to the Delhi High Court (India), and finally to the Supreme Court of India.

Legal Issues and Proceedings

Central legal issues included interpretation of Section 3(d) of the Patents Act, 1970 (India), which limits patentability for "new forms" of known substances unless enhanced efficacy is demonstrated. Parties debated standards from international instruments like the Agreement on Trade-Related Aspects of Intellectual Property Rights and jurisprudence from the European Court of Justice and Supreme Court of the United States. Novartis argued entitlement under doctrines such as novelty, inventive step, and industrial applicability, relying on decisions from the United Kingdom and United States Court of Appeals for the Federal Circuit, while opponents emphasized public health principles invoked in World Health Organization reports and precedent from Bayer v. Union of India-style litigations. The trial featured expert testimony on pharmaceutical chemistry, crystallography, and clinical efficacy, and invoked regulatory frameworks from agencies like the Central Drugs Standard Control Organization and the Drug Controller General of India.

Supreme Court Judgment (2013)

A three-judge bench of the Supreme Court of India dismissed Novartis's appeal, holding that the beta crystalline form did not meet the enhanced efficacy threshold under Section 3(d). The Court affirmed that Section 3(d) aims to prevent "evergreening" — a practice criticized by organizations such as Médecins Sans Frontières and Health Action International — where incremental changes secure new patents and extend market exclusivity. The judgment cited comparative jurisprudence including decisions from the European Patent Office Boards of Appeal and emphasized statutory text over expansive interpretations favored in some United States and European Union contexts. The ruling denied patent protection for Glivec's crystalline form, maintaining availability of generic imatinib produced by firms like Natco Pharma and Cipla.

Impact on Patent Law and Pharmaceutical Industry

The decision reinforced India's patentability threshold under Section 3(d), affecting licensing strategies of multinational firms such as Pfizer, Roche, Sanofi, and GlaxoSmithKline. It emboldened Indian generic manufacturers and influenced procurement policies of global health organizations like the Global Fund and UNICEF by preserving access to lower-cost antineoplastic and other medicines. The ruling featured in policy debates at forums like the World Trade Organization and informed national law reform discussions in countries considering similar anti-evergreening measures, including debates in the European Union and South Africa. Investors, patent offices, and patent attorneys adjusted patent prosecution, relying on claim-drafting approaches used in cases before the European Patent Office and the United States Patent and Trademark Office.

Reactions and Subsequent Developments

Reactions were polarized: public health advocates and civil society groups including Oxfam and Doctors Without Borders praised the judgment, while industry associations such as the International Federation of Pharmaceutical Manufacturers & Associations criticized it as inconsistent with global intellectual property norms. Novartis pursued other regulatory and commercial avenues, including voluntary licensing and negotiations under initiatives like the Medicines Patent Pool and bilateral access agreements with governments such as India and Bangladesh. The judgment has been cited in subsequent Indian cases and international commentary on patent policy, influencing litigation strategies in jurisdictions like the United States, United Kingdom, Brazil, and South Africa. Scholarly analysis appeared in journals associated with institutions such as Harvard Law School, Yale Law School, and Oxford University.

Category:Indian case law Category:Patent litigation Category:Pharmaceutical industry